Vistagen completes PALISADE-4 Phase 3 trial; topline results expected June 2026

Vistagen completed the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol for acute social anxiety disorder treatment, with results expected this month. The company also advanced a Phase 2 repeat dose study and received FDA approval to proceed with refisolone development for menopausal hot flashes, potentially supporting future NDA submissions.